February 15th, 2011
Last Thursday, two articles in the New England Journal of Medicine described exciting results with sunitinib (Sutent®) and everolimus (Afinitor®) from phase III clinical trials in pancreatic neuroendocrine tumors (PNET). To gauge the immediate impact these reports could have with the global oncology community, MDoutlook launched a global Quick Poll™ of its medical oncology members. Based on the initial results collected over the weekend:
• While 40-50% of oncologists are already using sunitinib or everolimus for the treatment of some of their patients with PNET, over 80% plan on using them in 2011
• The amount of patients with PNET who will receive sunitinib or everolimus for treatment in 2011 is predicted to expand by 2.5-3.0 fold over current levels (see figure below)
• Three quarters of oncologists expect their PNET patients will stay on extended therapy with these agents regardless of the potential for serious side effects
• Usage of these agents in PNET will have little to no effect on their use in metastatic renal cell carcinoma (where both currently have FDA-approval).
MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader composed-strategy councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 50,000 oncologists and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians
For more information about MDoutlook or to receive a final copy of this report when it is available next week, please email [email protected] or call +1.404.496.4136.